• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
OPT 4.19% 80.0¢

OPTHEA LIMITED - News & Media

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The... Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

No News & Media currently available.

(20min delay)
Last
80.0¢
Change
-0.035(4.19%)
Mkt cap ! $984.8M
Open High Low Value Volume
82.0¢ 82.8¢ 80.0¢ $2.636M 3.214M

Buyers (Bids)

No. Vol. Price($)
5 35676 80.0¢
 

Sellers (Offers)

Price($) Vol. No.
82.0¢ 73544 3
View Market Depth
Last trade - 16.10pm 01/11/2024 (20 minute delay) ?
Last
80.5¢
  Change
-0.035 ( 3.93 %)
Open High Low Volume
84.5¢ 84.5¢ 80.0¢ 760531
Last updated 15.59pm 01/11/2024 ?
OPT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.